AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018
September 24 2018 - 6:50AM
Business Wire
- Professor Jonathan Iredell to present
data from AmpliPhi Biosciences’ ongoing expanded access program for
bacteriophage product candidates AB-SA01 (targeting S. aureus) and
AB-PA01 (targeting P. aeruginosa)
AmpliPhi Biosciences Corporation (NYSE American: APHB), a
clinical-stage biotechnology company focused on precisely targeted
bacteriophage therapeutics for antibiotic-resistant infections,
today announced that clinical case series data from the company’s
expanded access program for its two investigational bacteriophage
therapeutics, AB-SA01 and AB-PA01, will be presented in an oral
abstract session “Novel Therapies for Superbugs” at IDWeek 2018,
being held October 3-7 in San Francisco.
Details of the oral abstract session are as follows:
Title: Safety and Efficacy of Bacteriophage Therapy:
Analysis of Clinical Case Series DataOral Abstract Session:
Novel Therapies for SuperbugsAbstract number:
1642Date/Time: Friday, October 5, 2018, 2:45 p.m.
PDTLocation: Room S 158Presenter: Prof. Jonathan
Iredell, Critical Infectious Diseases, Westmead Hospital and
Critical Infection, Westmead Institute for Medical Research,
Sydney, Australia
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a clinical-stage
biotechnology company focused on treating antibiotic-resistant
infections using its proprietary bacteriophage-based technology.
AmpliPhi’s lead clinical stage product candidates, AB-SA01 and
AB-PA01, target multidrug-resistant Staphylococcus aureus and
Pseudomonas aeruginosa, which are included on the WHO’s 2017
Priority Pathogens List. Phage therapeutics are uniquely positioned
to address the threat of antibiotic resistance as they can be
precisely targeted to kill select bacteria, have a differentiated
mechanism of action, can penetrate and disrupt biofilms (a common
bacterial defense mechanism against antibiotics), are potentially
synergistic with antibiotics and have been shown to restore
antibiotic sensitivity to drug-resistant bacteria. For more
information visit www.ampliphibio.com.
About Bacteriophages
Bacteriophages, or more simply “phages,” are the natural
predators of bacteria and are thought to be the most abundant life
form on earth. Phages have evolved an incredible diversity of
strains that typically prey upon just a few closely related strains
or species of bacteria, enabling phage therapies to precisely
target pathogenic bacteria while sparing the beneficial microbiota.
Phages can infect and kill bacteria, whether they are
antibiotic-resistant or not, and even when they have formed
protective biofilms.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180924005281/en/
At the Company:AmpliPhi BiosciencesMatthew Dansey,
858-800-4869md@ampliphibio.comorInvestor Relations:Westwicke
PartnersRobert H. Uhl, 858-356-5932robert.uhl@westwicke.com
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Apr 2023 to Apr 2024